Abstract
PurposeThis retrospective case-series study evaluated efficacy and safety of Endostar combined with chemotherapy in the treatment of advanced bone and soft tissue sarcomas in stage IV.Materials and MethodsForty-seven patients diagnosed with stage IV bone and soft tissue sarcomas and treated with chemotherapy in Tianjin Medical University Cancer Institute & Hospital were reviewed. Of these patients, 23 patients were treated with Endostar plus chemotherapy (designated as combined group), and 24 patients received only chemotherapy (designated as control group). Progression-free survival (PFS), overall survival (OS), objective response rate (ORR) and clinical benefit response (CBR) were analyzed to find the difference between these two groups with the purpose to investigate the role of Endostar in metastatic sarcomas.ResultsEndostar combined with chemotherapy had significantly increased PFS. In the combined group and control groups, the median PFS (8.6 months versus 4.4 months) and the CBR (47.8% versus 16.7%) showed significant difference (P = 0.032), while the median overall survival (11.7 months versus 10.6 months, P = 0.658) and the ORR (17.4% versus 8.3%, P = 0.167) showed no significant difference. The common grade 3-4 side effects for both groups were myelosuppression and transient elevation of transaminases.ConclusionEndostar combined with chemotherapy had significant activity to increase the PFS and improve CBR in patients with advanced sarcomas, with tolerable side effects.
Highlights
Sarcoma, a heterogeneous group of malignancies that arise from mesenchymal tissue, is mainly divided into two categories: soft tissue sarcoma and bone sarcoma
Between June 2008 and December 2015, a total of 47 patients diagnosed with advanced bone and soft tissue sarcomas in stage IV were treated with chemotherapy. 23 patients with sarcomas in stage IV were treated with Endostar combined chemotherapy
While in the same period, 24 metastatic sarcoma patients received only chemotherapy because of the poor economic status and/or the apprehensions about Endostar. We reviewed these 47 cases with the purpose to investigate the role of Endostar combined with chemotherapy
Summary
A heterogeneous group of malignancies that arise from mesenchymal tissue, is mainly divided into two categories: soft tissue sarcoma and bone sarcoma. Soft tissue sarcomas (STS) include more than 50 different subtypes: the most common pleomorphic undifferentiated sarcoma (25% ~ 35%), followed by liposarcoma (25% ~ 30%), leiomyosarcoma (12%), synovial sarcoma (10%) and malignant peripheral nerve sheath tumor (6%) [2]. Despite the different pathological types, the 10% patients with high-grade STS already have metastasis when newly diagnosed [3]. Osteosarcoma is the most common primary malignant tumor, common in children and young adolescents and the osteosarcoma was newly diagnosed with the distant metastasis rate of 20% ~ 40% [3, 4]. The lung is the most common site of metastasis in patients with bone and soft tissue sarcomas
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
